Live Breaking News & Updates on Part Of Company Site Consolidation

Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
March 17, 2021 07:30 ET
| Source:
Interpace Biosciences, Inc.
Interpace Biosciences, Inc.
Part of Company’s Site Consolidation and Cost Savings Measures
Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (DiamiR). This sale is in line with previously announced restructuring and cost reduction initiatives announced by Interpace. Under this agreement, DiamiR will provide overflow lab testing in support of the Company’s molecular thyroid testing products at its main laboratory in Pittsburgh, PA. DiamiR will also support specific Interpace assay development and validation services on behalf of the Company for the next three quarters. Subject to specific ter ....

Megan Paul , Interpace Bioscience , Interpace Biopharma , Tom Burnell , Interpace Biosciences Inc , Haven Laboratory , Securities Exchange , Part Of Company Site Consolidation , Edison Group , Site Consolidation , Cost Savings , New Haven , Diamir Biosciences , New Haven Laboratory , Interpace Biosciences , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Best Market , Annual Report , Current Reports , Quarterly Reports , Otc Markets Idxg , Otc Idxg , New Haven Clia Lab To Diamir , Cost Savings Measures ,